Video

Next-Generation RNA Modality Supply Considerations

Source: Advancing RNA

Together, Life Edit Therapeutics’ April Sena and Sanofi’s Troiano share their perspectives on raw material quality & IP-related considerations for managing the supply chain for next-generation RNA modalities — namely ex-vivo gene editing agents comprising mRNA or circular RNA — as well as for LNPs.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Advancing RNA? Subscribe today.

Subscribe to Advancing RNA X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Advancing RNA

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)